Physician
Endocrinology
Dr. Allen B. King, MD
|
|
Give Review
Allen B. King, MD is an expert in the field of Endocrinology. He attended Creighton University School of Medicine. Creighton University School of Medicine is ranked 79 in research and 78 in primary care medicine He received 1 awards: "Fellow (FACE)". Allen King is also a published doctor. He has 29 paper published. The most recent paper is: Omitting late-night eating may cause hypoglycemia in "well controlled" Basal insulin-treated type 2 diabetes. Allen B. King is registered with Medicare.
Publications
- Omitting late-night eating may cause hypoglycemia in "well controlled" Basal insulin-treated type 2 Diabetes.
- Reassessment of insulin dosing guidelines in continuous subcutaneous insulin infusion treated type 1 Diabetes.
- Integrating advances in insulin into clinical practice: advances in insulin formulations.
- When is Enough, Enough? The Correlation Between once-daily Basal Insulin Doses to the Fasting Plasma Glucose in Type 2 Diabetes.
- The Number of Basal Rates Required to Achieve Near-Normal Basal Glucose Control in Pump-Treated Type 2 Diabetes.
- Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 Diabetes treated with once-nightly insulin glargine.
- Accuracy of dosage volume for halfway doses in the victoza pen.
- How much do I give? Reevaluation of insulin dosing estimation formulas using continuous glucose monitoring.
- Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 Diabetes patients.
- No higher dose requirements with insulin detemir than glargine in type 2 Diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring.
- Re: Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio.
- Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
- Evaluation of a Diabetes specialist-guided primary care Diabetes treatment program.
- The variable weight effect of exenatide treatment.
- Evaluation of a patient education booklet (SimpleStart) effect on postprandial glucose control in type 2 Diabetes.
- A prospective evaluation of insulin dosing recommendations in patients with type 1 Diabetes at near normal glucose control: bolus dosing.
- A prospective evaluation of insulin dosing recommendations in patients with type 1 Diabetes at near normal glucose control: Basal dosing.
- Clinical observations of exenatide treatment.
- Daily glucose trend analyses and treatment adjustments using the continuous glucose monitoring system (CGMS, Medtronic MiniMed): "tweaking".
- A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine.
- Comparison of glycemic and lipid response to pioglitazone treatment in Mexican-Americans and non-Hispanic Caucasians with type 2 Diabetes.
- Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 Diabetes mellitus: a retrospective review of randomly sele...
- Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
- Basal bolus dosing: a clinical experience.
- Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs.
- Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 Diabetes and a baseline A1C <8.0%.
- Titrating beyond glycemic goal: "post-glycemic target phenomenon".
- Weight versus Pre-Insulin-Treatment Assessment of Insulin Sensitivity to Determine the Starting Basal Insulin Dose: A Faster Way to Get to Goal?
Schools
Creighton University
University Colo Med Center
Stanford Med Center
Conditions Treated
- Adrenal Insufficiency
- Calcium Metabolism Disorders
- Diabetes Type 1
- Diabetes Type 2
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
- Choice Plus POS II
- Benesys
- Blue Card PPO
- Blue Cross Blue Shield of California PPO
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- HealthSmart
- Humana
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Fellow (FACE)
Education
-
University of Colorado -
Creighton University -
Creighton University School of Medicine
Drug Facts
| NPI NUMBER | 1649253048 | |
| NPPES Provider LastName | KING | |
| NPPES Provider FirstName | ALLEN | |
| NPPES Provider ZIPCode | 939012288 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 5659.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 0.28 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1649253048 |
| Last Name Of The Provider | KING |
| First Name Of The Provider | ALLEN |
| View All |
Similar Doctors
|
|
Dr. Karen L. Winn, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chengyu Xu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Haleh G. Bassiri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert R. Revers, MD
This Doctor is OpenDoctor Recommended.
|